FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 32

Author

Admin 425 posts 0 comments

Whitepaper

The New Imperative for CFOs and CHROs

Admin Mar 14, 2025
With costs continuing to increase significantly influenced by many factors, managing escalating benefits costs…
Whitepaper

The rise of open banking consumer report

Admin Mar 13, 2025
Seldom is a whole landscape changed by a singular innovation, but when it happens, it’s undeniable. Online retail,…
Whitepaper

PSD2 and Open Banking Without Pain

Admin Mar 12, 2025
The European Union’s Second Payment Services Directive (PSD2) signaled a new era of change and innovation in the…
Past Conference

Achieving Financial Inclusion through the Cloud

Admin Mar 11, 2025
Over the past decade, cloud computing has revolutionized how people and organizations work around the world by…
Whitepaper

How to Measure the Financial Impact of Physical Risks

Admin Mar 11, 2025
Physical risks resulting from climate change can be acute (driven by an event such as a flood or storm) or chronic…
Whitepaper

Sage Intacct | Overcoming Financial Growing Pains in Professional Services…

Admin Mar 10, 2025
Overcome Financial Growing Pains to Drive Profitability Growing organizations face common challenges like…
Whitepaper

Maximising Financial Impact : Building the Business Case for Source-to-Pay

Admin Mar 7, 2025
Finance professionals face growing challenges in sourcing, procurement, and accounts payable (AP). Key obstacles…
Whitepaper

How Wealth and Asset management firms thrive with Sage Intacct

Admin Mar 6, 2025
Optimizing Financial Performance in Wealth & Asset Management with Sage Intacct Wealth and asset management…
Featured News

Finance Process Improvement & the Global Process Owner Role

Admin Mar 4, 2025
This webinar, scheduled for October 31, 2024, will provide finance leaders with a comprehensive understanding of…
Whitepaper

The future of financial services: better customer experiences start with…

Admin Mar 3, 2025
Over the last few years, consumers have shown extraordinary resilience through much uncertainty. Many have adapted…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • Future of Finance: Review on the outlook for the UK financial system
    • FinTech and Employee F&F Settlement: How Digital Financial Platforms Are Transforming the Employee Exit Process
    • How AI and Digital Innovation Are Transforming the Future of the FinTech Industry
    • The Power of Ecosystems for Banking
    • The Rise of Fintech: Transforming the Financial Landscape

    ARTICLE

    BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
    2026-08-13T21:42:56Z
    PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the...


    BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
    2026-08-13T21:30:00Z
    MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended...


    Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
    2026-08-13T21:02:00Z
    TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced financial...


    NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
    2026-08-13T21:00:42Z
    ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and...


    Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    2026-08-13T21:00:00Z
    DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial...


    Maze Therapeutics Announces Appointments to Its Board of Directors
    2026-08-13T20:42:25Z
    Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience


    Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:30:00Z
    Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027


    Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-13T20:25:51Z
    Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the...


    Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
    2026-08-13T20:20:00Z
    -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026...


    Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
    2026-08-13T20:15:00Z
    TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three...


    Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
    2026-08-13T20:15:00Z
    AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027


    Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
    2026-08-13T20:15:00Z
    Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding


    Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
    2026-08-13T20:15:00Z
    A patient-centered initiative focused on education, connection, and support


    Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
    2026-08-13T20:15:00Z
    HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today...


    Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
    2026-08-13T20:10:00Z
    Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track


    Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
    2026-08-13T20:06:35Z
    MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today...


    Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:05:00Z
    NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.


    Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    2026-08-13T20:05:00Z
    RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions...


    Glass House Brands Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    LONG BEACH, Calif. and TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis...


    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    2026-08-13T20:05:00Z
    BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that...


    Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:05:00Z
    Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026


    MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
    2026-08-13T20:05:00Z
    ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial...


    ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
    2026-08-13T20:05:00Z
    PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf...


    CapsoVision Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and...


    Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update
    2026-08-13T20:05:00Z
    Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing


    4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
    2026-08-13T20:05:00Z
    EMERYVILLE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to...


    CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights  
    2026-08-13T20:05:00Z
    Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this...


    Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-13T20:05:00Z
    Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter


    Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...


    Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-13T20:05:00Z
    Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.